-
Article
Open AccessDetermining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms
Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap clinically. Using machine learnin...
-
Article
Open AccessSurvival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patien...
-
Article
Open AccessAllele-specific DNA methylation is increased in cancers and its dense map** in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs
Map** of allele-specific DNA methylation (ASM) can be a post-GWAS strategy for localizing regulatory sequence polymorphisms (rSNPs). The advantages of this approach, and the mechanisms underlying ASM in norm...
-
Article
Open AccessDurable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
-
Article
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial
In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we desc...
-
Article
Open AccessObservational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
The observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance.
-
Article
Open AccessThe serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer
Ovarian cancer (OVC) is the deadliest of all gynecologic cancers, primarily as a consequence of asymptomatic progression. The complex nature of OVC creates challenges for early detection, and there is a lack o...
-
Article
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Clinical testing of BCR inhibition on DLBCL reveals determinants of response.
-
Article
Open AccessClinical decision support systems for improving diagnostic accuracy and achieving precision medicine
As research laboratories and clinics collaborate to achieve precision medicine, both communities are required to understand mandated electronic health/medical record (EHR/EMR) initiatives that will be fully im...
-
Article
Open AccessKallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes
Early detection of ovarian cancer remains a challenge due to widespread metastases and a lack of biomarkers for early-stage disease. This study was conducted to identify relevant biomarkers for both laparoscop...
-
Article
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
Purpose CD37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic that triggers direct caspase in...
-
Article
Open AccessPhase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
Purpose Amplification or over-expression of the mitotic Aurora A kinase (AAK) has been reported in several heme-lymphatic malignancies. MLN8237 (alisertib) is a novel inhibitor of AAK tha...
-
Article
Open AccessFibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
High risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of pa...
-
Chapter
Bortezomib in Mantle Cell Lymphoma
Since its recognition as a separate subtype of non-Hodgkin lymphoma (NHL) in 1994, mantle cell lymphoma (MCL) has been a very active field of clinical research due to its typical poor outcome. Besides a small ...
-
Chapter
Infections in Patients with Hematologic Malignancies Treated with Monoclonal Antineoplastic Therapy
The advent of monoclonal antibody therapy heralded a new era in oncology. In 1997, rituximab became the first monoclonal antibody for the treatment of cancer following its approval for patients with B-cell non...
